nifedipine has been researched along with Diabetic Nephropathies in 40 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy of an angiotensin converting enzyme (ACE) inhibitor (perindopril), a dihydropyridine calcium channel blocker (sustained release nifedipine) and placebo in preventing the progression of albuminuria and decline in glomerular filtration rate (GFR) in patients with Type 2 diabetes and microalbuminaria." | 9.11 | Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. ( Allen, TJ; Campbell, DJ; Cooper, ME; Gilbert, RE; Hammond, JJ; Jerums, G; O'Brien, RC; Raffaele, J; Tsalamandris, C, 2004) |
| "Our data show that both lisinopril and nifedipine are effective in delaying the occurrence of macroalbuminuria in normotensive IDDM patients with MA." | 9.08 | Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. ( Carta, Q; Crepaldi, G; Deferrari, G; Mangili, R; Navalesi, R; Nosadini, R; Santeusanio, F; Spalluto, A; Vanasia, A; Villa, GM, 1998) |
| "This study aimed to evaluate the efficacy of nifedipine controlled-release tablets combined with sacubitril valsartan in diabetic nephropathy (DN) patients with hypertension." | 8.31 | Therapeutic improvements of nifedipine controlled-release tablets combined with sacubitril valsartan on patients with diabetic nephropathy complicated with hypertension. ( Hu, L; Liu, G; Wei, Y, 2023) |
| " Reduction of microalbuminuria at 27 weeks, compared to the vehicle group, was 37% and 52% in the enalapril- and nilvadipine-treated groups, respectively." | 7.72 | Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes. ( Imai, E; Moriyama, T; Oka, K; Ueda, H, 2004) |
| " In the first 3 months, drug dosage was titrated to achieve a decrease in diastolic blood pressure of at least 5 mm HG: Thirty-three patients had a minimum of 24 months' data, and 25 patients were followed up beyond 36 months (mean, 67 +/- 4 months)." | 6.70 | Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. ( Allen, TJ; Campbell, DJ; Cooper, ME; Gilbert, RE; Hammond, JJ; Jerums, G; Raffaele, J; Tsalamandris, C, 2001) |
| "Treatment with enalapril for 48 months may have a beneficial effect on the decline of microalbumin excretion in NIDDM patients." | 6.67 | Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. ( Hara, T; Hotta, N; Kawamura, T; Matsumae, H; Matsuo, S; Nakayama, M; Sakamoto, N; Sano, T; Sasaki, H, 1994) |
| "Twelve patients with type 1 diabetes with albuminuria, mild to moderate hypertension and a serum creatinine level of less than 200 mumol l-1 were included." | 6.67 | Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. ( Berg, KJ; Djøseland, O; Endresen, L; Fauchald, P; Hartmann, A; Holdaas, H; Jervell, J; Lien, MG; Nilsen, L, 1991) |
| "Twenty-five stage 2 diabetic nephropathy patients, 39 stage 3 diabetic nephropathy patients, and 12 nondiabetic subjects performed five submaximal cycloergometric exercises (90% of theoretical heart rate) on nonconsecutive days." | 6.67 | Short-term administration of captopril and nifedipine and exercise-induced albuminuria in normotensive diabetic patients with early-stage nephropathy. ( Bossoni, S; Caldonazzo, A; Cimino, A; Cravarezza, P; Giustina, A; Giustina, G; Romanelli, G, 1990) |
| " Dosage of nifedipine or efonidipine was chosen after preliminary studies demonstrated that it showed moderate antihypertensive action (more than a 20% decrease in systemic blood pressure after treatment)." | 5.30 | Effects of the antihypertensive drug nifedipine on albuminuria and renal histopathology in young spontaneously hypertensive rats with diabetes. ( Kaneko, S; Shou, I; Takeda, M; Takizawa, H; Tomino, Y, 1999) |
| "To assess the efficacy of an angiotensin converting enzyme (ACE) inhibitor (perindopril), a dihydropyridine calcium channel blocker (sustained release nifedipine) and placebo in preventing the progression of albuminuria and decline in glomerular filtration rate (GFR) in patients with Type 2 diabetes and microalbuminaria." | 5.11 | Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. ( Allen, TJ; Campbell, DJ; Cooper, ME; Gilbert, RE; Hammond, JJ; Jerums, G; O'Brien, RC; Raffaele, J; Tsalamandris, C, 2004) |
| " A total of 54 type 1 diabetic patients with albuminuria and blood pressure (BP) <150/90 mmHg were randomized to receive 10 mg enalapril once daily, 10 mg nifedipine retard twice daily, or placebo in a multicenter double-blind study of 3 years' duration." | 5.09 | Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT). ( , 2001) |
| " Angiotensin converting enzyme inhibitors (ACE-I) significantly retarded the development of end-stage renal failure compared to antihypertensives other than ACE-I (mostly nifedipine), and the effect was evident particularly in patients with proteinuria below the median (2." | 5.08 | Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. ( Babazono, T; Hirayama, M; Ishii, A; Omori, Y; Takahashi, C; Takeda, M; Tomonaga, O; Ujihara, U; Yokoyama, H, 1997) |
| "Our data show that both lisinopril and nifedipine are effective in delaying the occurrence of macroalbuminuria in normotensive IDDM patients with MA." | 5.08 | Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. ( Carta, Q; Crepaldi, G; Deferrari, G; Mangili, R; Navalesi, R; Nosadini, R; Santeusanio, F; Spalluto, A; Vanasia, A; Villa, GM, 1998) |
| "At 21 months, both patient groups had similar levels of blood pressure control, however, only the diltiazem group had a change in proteinuria (4+/-10%delta, nifedipine vs." | 5.08 | Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. ( Bakris, GL; Smith, AC; Toto, R, 1998) |
| "In the patients treated with enalapril, albuminuria decreased from 143 +/- 64 (mean +/- SD) mg/24 h to 122 +/- 67 mg/24 h during the first year." | 5.07 | Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. ( Bental, T; Jutrin, I; Katz, B; Lishner, M; Ravid, M; Savin, H, 1993) |
| " We, along with others, have recently found that nifedipine, one of the most widely used DHPs, inhibits apoptotic cell death of endothelial cells (ECs) as well as vascular inflammation and subsequently improves endothelial function in patients with cardiovascular risk factors, including hypertension and/or diabetes, thus slowing the development and progression of atherosclerosis in these patients." | 4.84 | Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. ( Matsui, T; Nakamura, K; Yamagishi, S, 2008) |
| "This study aimed to evaluate the efficacy of nifedipine controlled-release tablets combined with sacubitril valsartan in diabetic nephropathy (DN) patients with hypertension." | 4.31 | Therapeutic improvements of nifedipine controlled-release tablets combined with sacubitril valsartan on patients with diabetic nephropathy complicated with hypertension. ( Hu, L; Liu, G; Wei, Y, 2023) |
| " Reduction of microalbuminuria at 27 weeks, compared to the vehicle group, was 37% and 52% in the enalapril- and nilvadipine-treated groups, respectively." | 3.72 | Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes. ( Imai, E; Moriyama, T; Oka, K; Ueda, H, 2004) |
| "A 66-year-old hypertensive diabetic patient with latent hypoaldosteronism and mild renal failure was treated by adding enalapril, an angiotensin converting enzyme inhibitor, to the furosemide and nifedipine regimen because of an insufficient antihypertensive response for 1 month." | 3.69 | Reversible hyperkalemia during antihypertensive therapy in a hypertensive diabetic patient with latent hypoaldosteronism and mild renal failure. ( Azukizawa, S; Kaneko, M; Kigoshi, T; Matsui, A; Morimoto, S; Nakano, S; Uchida, K, 1994) |
| " In the first 3 months, drug dosage was titrated to achieve a decrease in diastolic blood pressure of at least 5 mm HG: Thirty-three patients had a minimum of 24 months' data, and 25 patients were followed up beyond 36 months (mean, 67 +/- 4 months)." | 2.70 | Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. ( Allen, TJ; Campbell, DJ; Cooper, ME; Gilbert, RE; Hammond, JJ; Jerums, G; Raffaele, J; Tsalamandris, C, 2001) |
| "Treatment with enalapril for 48 months may have a beneficial effect on the decline of microalbumin excretion in NIDDM patients." | 2.67 | Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. ( Hara, T; Hotta, N; Kawamura, T; Matsumae, H; Matsuo, S; Nakayama, M; Sakamoto, N; Sano, T; Sasaki, H, 1994) |
| "Twelve patients with type 1 diabetes with albuminuria, mild to moderate hypertension and a serum creatinine level of less than 200 mumol l-1 were included." | 2.67 | Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. ( Berg, KJ; Djøseland, O; Endresen, L; Fauchald, P; Hartmann, A; Holdaas, H; Jervell, J; Lien, MG; Nilsen, L, 1991) |
| "Twenty-five stage 2 diabetic nephropathy patients, 39 stage 3 diabetic nephropathy patients, and 12 nondiabetic subjects performed five submaximal cycloergometric exercises (90% of theoretical heart rate) on nonconsecutive days." | 2.67 | Short-term administration of captopril and nifedipine and exercise-induced albuminuria in normotensive diabetic patients with early-stage nephropathy. ( Bossoni, S; Caldonazzo, A; Cimino, A; Cravarezza, P; Giustina, A; Giustina, G; Romanelli, G, 1990) |
| "We examined renal responses to a pharmacological dosage of human atrial natriuretic peptide (hANP) and the potential interference of nifedipine administration with the effects of hANP on kidney function in healthy subjects and normoglycemic patients with type 1 diabetes mellitus." | 2.66 | Effects of nifedipine on renal responses to human atrial natriuretic peptide in healthy subjects and normoglycemic patients with type 1 diabetes mellitus. ( Hofmann, E; Jungmann, E; Scheuermann, EH; Schöffling, K; Seel, K, 1989) |
| "GW9662 treatment alone was found to increase RAGE mRNA levels in tubular cells." | 1.36 | Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation. ( Fukami, K; Matsui, T; Okuda, S; Takeuchi, M; Ueda, S; Yamagishi, S, 2010) |
| "Nifedipine was used for hypertension in 33% of SPK and was associated with better CV and amplitudes, particularly in the upper limbs, where there was less neuropathy." | 1.30 | Diabetic neuropathy after pancreas transplantation: determinants of recovery. ( Al-Harbi, IS; Allen, RD; Chapman, JR; Clouston, PD; Morris, JG; Nankivell, BJ; O'Connell, PJ, 1997) |
| " Dosage of nifedipine or efonidipine was chosen after preliminary studies demonstrated that it showed moderate antihypertensive action (more than a 20% decrease in systemic blood pressure after treatment)." | 1.30 | Effects of the antihypertensive drug nifedipine on albuminuria and renal histopathology in young spontaneously hypertensive rats with diabetes. ( Kaneko, S; Shou, I; Takeda, M; Takizawa, H; Tomino, Y, 1999) |
| "Treatment with nifedipine was associated with the return of [Ca2+]i toward normal values in both the nondiabetic (51 +/- 4." | 1.29 | Effect of treatment of hemodialysis patients with nifedipine on metabolism and function of polymorphonuclear leukocytes. ( Akmal, M; Alexiewicz, JM; Klin, M; Massry, SG; Smogorzewski, M, 1995) |
| "Diabetic nephropathy is the dominant cause of hypertension in insulin-dependent diabetics, and long-term rigid antihypertensive treatment inhibits the progression of nephropathy, probably even when there is renal insufficiency." | 1.28 | The effect of antihypertensive treatment on kidney function in insulin-dependent (type I) diabetics with renal failure. ( Conde, N; Gums, G; Heinke, P; Schulz, B; Strese, J; Zander, E; Zander, G, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (7.50) | 18.7374 |
| 1990's | 23 (57.50) | 18.2507 |
| 2000's | 9 (22.50) | 29.6817 |
| 2010's | 4 (10.00) | 24.3611 |
| 2020's | 1 (2.50) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, Y | 1 |
| Hu, L | 1 |
| Liu, G | 1 |
| Ishizawa, K | 1 |
| Izawa-Ishizawa, Y | 1 |
| Yamano, N | 1 |
| Urushihara, M | 1 |
| Sakurada, T | 1 |
| Imanishi, M | 1 |
| Fujii, S | 1 |
| Nuno, A | 1 |
| Miyamoto, L | 1 |
| Kihira, Y | 1 |
| Ikeda, Y | 1 |
| Kagami, S | 1 |
| Kobori, H | 1 |
| Tsuchiya, K | 1 |
| Tamaki, T | 1 |
| Yamagishi, S | 3 |
| Matsui, T | 2 |
| Takeuchi, M | 1 |
| Ueda, S | 1 |
| Fukami, K | 1 |
| Okuda, S | 1 |
| Sepehr-Ara, L | 1 |
| Sepehr-Ara, M | 1 |
| Mahmoudian, M | 1 |
| White, KE | 1 |
| Bilous, RW | 1 |
| Marshall, SM | 1 |
| El Nahas, M | 1 |
| Remuzzi, G | 1 |
| Piras, G | 1 |
| De Cosmo, S | 1 |
| Viberti, G | 1 |
| Moriyama, T | 1 |
| Oka, K | 1 |
| Ueda, H | 1 |
| Imai, E | 1 |
| Jerums, G | 2 |
| Allen, TJ | 2 |
| Campbell, DJ | 2 |
| Cooper, ME | 2 |
| Gilbert, RE | 2 |
| Hammond, JJ | 2 |
| O'Brien, RC | 1 |
| Raffaele, J | 2 |
| Tsalamandris, C | 2 |
| Yoshino, G | 1 |
| Nakamura, K | 1 |
| Dohmen, W | 1 |
| Parving, HH | 1 |
| Rossing, P | 1 |
| Hommel, E | 1 |
| Smidt, UM | 1 |
| Petitjean, P | 1 |
| Vloemans, M | 1 |
| Barthelmebs, M | 1 |
| Stephan, D | 1 |
| Grima, M | 1 |
| Jund, A | 1 |
| Imbs, JL | 1 |
| Alexiewicz, JM | 1 |
| Smogorzewski, M | 1 |
| Klin, M | 1 |
| Akmal, M | 1 |
| Massry, SG | 1 |
| Uchida, K | 1 |
| Azukizawa, S | 1 |
| Nakano, S | 1 |
| Kaneko, M | 1 |
| Kigoshi, T | 1 |
| Morimoto, S | 1 |
| Matsui, A | 1 |
| Sano, T | 1 |
| Kawamura, T | 1 |
| Matsumae, H | 1 |
| Sasaki, H | 1 |
| Nakayama, M | 1 |
| Hara, T | 1 |
| Matsuo, S | 1 |
| Hotta, N | 1 |
| Sakamoto, N | 1 |
| O'Donnell, MJ | 1 |
| Rowe, BR | 1 |
| Lawson, N | 1 |
| Horton, A | 1 |
| Gyde, OH | 1 |
| Barnett, AH | 2 |
| Ravid, M | 1 |
| Savin, H | 1 |
| Jutrin, I | 1 |
| Bental, T | 1 |
| Katz, B | 1 |
| Lishner, M | 1 |
| Bakris, GL | 3 |
| Smith, A | 1 |
| Agardh, CD | 1 |
| Garcia-Puig, J | 1 |
| Charbonnel, B | 1 |
| Angelkort, B | 1 |
| Allen, RD | 1 |
| Al-Harbi, IS | 1 |
| Morris, JG | 1 |
| Clouston, PD | 1 |
| O'Connell, PJ | 1 |
| Chapman, JR | 1 |
| Nankivell, BJ | 1 |
| Yokoyama, H | 1 |
| Tomonaga, O | 1 |
| Hirayama, M | 1 |
| Ishii, A | 1 |
| Takeda, M | 2 |
| Babazono, T | 1 |
| Ujihara, U | 1 |
| Takahashi, C | 1 |
| Omori, Y | 1 |
| Hess, B | 1 |
| Crepaldi, G | 1 |
| Carta, Q | 1 |
| Deferrari, G | 1 |
| Mangili, R | 1 |
| Navalesi, R | 1 |
| Santeusanio, F | 1 |
| Spalluto, A | 1 |
| Vanasia, A | 1 |
| Villa, GM | 1 |
| Nosadini, R | 1 |
| Smith, AC | 1 |
| Toto, R | 1 |
| Kaneko, S | 1 |
| Takizawa, H | 1 |
| Shou, I | 1 |
| Tomino, Y | 1 |
| Baba, S | 1 |
| Hironaka, K | 1 |
| Makino, H | 1 |
| Kumagai, I | 1 |
| Haramoto, T | 1 |
| Yamasaki, Y | 1 |
| Shikata, K | 1 |
| Takahashi, M | 1 |
| Nishii, M | 1 |
| Ota, Z | 1 |
| Holdaas, H | 1 |
| Hartmann, A | 1 |
| Lien, MG | 1 |
| Nilsen, L | 1 |
| Jervell, J | 1 |
| Fauchald, P | 1 |
| Endresen, L | 1 |
| Djøseland, O | 1 |
| Berg, KJ | 1 |
| Romanelli, G | 2 |
| Giustina, A | 2 |
| Cravarezza, P | 2 |
| Caldonazzo, A | 2 |
| Agabiti-Rosei, E | 1 |
| Giustina, G | 2 |
| Washio, M | 1 |
| Onoyama, K | 1 |
| Makita, Y | 1 |
| Fujishima, M | 1 |
| Fujimi, S | 1 |
| Bossoni, S | 1 |
| Cimino, A | 1 |
| Demarie, BK | 1 |
| Zander, E | 1 |
| Conde, N | 1 |
| Heinke, P | 1 |
| Zander, G | 1 |
| Strese, J | 1 |
| Gums, G | 1 |
| Schulz, B | 1 |
| Jungmann, E | 1 |
| Seel, K | 1 |
| Hofmann, E | 1 |
| Scheuermann, EH | 1 |
| Schöffling, K | 1 |
| Mimran, A | 2 |
| Insua, A | 2 |
| Ribstein, J | 2 |
| Monnier, L | 1 |
| Bringer, J | 1 |
| Mirouze, J | 1 |
3 reviews available for nifedipine and Diabetic Nephropathies
| Article | Year |
|---|---|
[Calcium antagonists: current and future applications based on new evidence. Calcium antagonists and diabetes].
Topics: Antioxidants; Calcium Channel Blockers; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Reti | 2010 |
[J-MIND study: effect of nifedipine on renal function in Japanese hypertensive patients with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabet | 2006 |
Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine.
Topics: Antioxidants; Apoptosis; Atherosclerosis; Calcium Channels; Cardiovascular Diseases; Cytokines; Diab | 2008 |
22 trials available for nifedipine and Diabetic Nephropathies
| Article | Year |
|---|---|
Podocyte number in normotensive type 1 diabetic patients with albuminuria.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Blood Pressure; Calcium Channe | 2002 |
Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Mel | 2004 |
[Investigation on the blood pressure-independent nephroprotective effect of nilvadipine in type 2 diabetics].
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; | 2008 |
Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Bendroflumethiazide; Blood Pressure; C | 1995 |
Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients.
Topics: Acetylglucosaminidase; Albuminuria; beta 2-Microglobulin; Blood Pressure; Body Weight; Cholesterol; | 1994 |
Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel B | 1993 |
Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.
Topics: Adult; Albuminuria; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; D | 1993 |
Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists.
Topics: Aged; Albuminuria; Antihypertensive Agents; Calcium Channel Blockers; Clonidine; Cross-Over Studies; | 1996 |
Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine.
Topics: Adolescent; Adult; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blin | 1996 |
Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel B | 1997 |
Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM.
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Creatinine; Diab | 1998 |
Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy.
Topics: Adult; Aged; Calcium Channel Blockers; Diabetic Nephropathies; Diltiazem; Female; Humans; Kidney Glo | 1998 |
Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT).
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium | 2001 |
Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria.
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Age | 2001 |
Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Disea | 2001 |
Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Biological Transport; Blood Pressure; | 1991 |
Albuminuria induced by exercise in hypertensive type I and type II diabetic patients: a randomised, double-blind study on the effects of acute administration of captopril and nifedipine.
Topics: Adolescent; Adult; Albuminuria; Blood Pressure; Captopril; Diabetes Mellitus, Type 1; Diabetes Melli | 1991 |
Short-term administration of captopril and nifedipine and exercise-induced albuminuria in normotensive diabetic patients with early-stage nephropathy.
Topics: Administration, Oral; Adolescent; Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Capt | 1990 |
Effects of different calcium antagonists on proteinuria associated with diabetes mellitus.
Topics: Aged; Creatinine; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Di | 1990 |
Effects of nifedipine on renal responses to human atrial natriuretic peptide in healthy subjects and normoglycemic patients with type 1 diabetes mellitus.
Topics: Administration, Buccal; Adult; Albuminuria; Atrial Natriuretic Factor; Blood Pressure; Diabetes Mell | 1989 |
Contrasting effects of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy.
Topics: Adolescent; Adult; Blood Pressure; Captopril; Diabetic Nephropathies; Female; Humans; Kidney; Male; | 1988 |
Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy.
Topics: Adult; Albuminuria; Blood Pressure; Captopril; Clinical Trials as Topic; Diabetes Mellitus, Type 1; | 1988 |
15 other studies available for nifedipine and Diabetic Nephropathies
| Article | Year |
|---|---|
Therapeutic improvements of nifedipine controlled-release tablets combined with sacubitril valsartan on patients with diabetic nephropathy complicated with hypertension.
Topics: Biphenyl Compounds; Delayed-Action Preparations; Diabetes Mellitus; Diabetic Nephropathies; Drug Com | 2023 |
Nitrosonifedipine ameliorates the progression of type 2 diabetic nephropathy by exerting antioxidative effects.
Topics: Animals; Antioxidants; Cell Line; Diabetic Nephropathies; Humans; Male; Mice; Mice, Inbred C57BL; Mi | 2014 |
Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation.
Topics: Anilides; Calcium Channel Blockers; Cells, Cultured; Diabetic Nephropathies; Glycation End Products, | 2010 |
Effect of the two new calcium channel blockers mebudipine and dibudipine in comparison to amlodipine on vascular flow of isolated kidney of diabetic rat.
Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diab | 2010 |
Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body | 2004 |
Short-term effects of quinapril and nifedipine on early renal changes in streptozotocin-induced diabetes in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Body Weight; Carbon Dioxide; Diabe | 1994 |
Effect of treatment of hemodialysis patients with nifedipine on metabolism and function of polymorphonuclear leukocytes.
Topics: Adenosine Triphosphate; Adult; Animals; Calcium; Diabetic Nephropathies; Female; Humans; Kidney Fail | 1995 |
Reversible hyperkalemia during antihypertensive therapy in a hypertensive diabetic patient with latent hypoaldosteronism and mild renal failure.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Enalapril; Furos | 1994 |
Diabetic neuropathy after pancreas transplantation: determinants of recovery.
Topics: Adult; Body Weight; Calcium Channel Blockers; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dia | 1997 |
Reduced proteinuria after cessation of long-acting, osmotic release nifedipine GITS in diabetic nephropathy.
Topics: Aged; Calcium Channel Blockers; Delayed-Action Preparations; Diabetic Nephropathies; Female; Humans; | 1997 |
Which one of the following antihypertensive medications is the least appropriate choice for patients with diabetic nephropathy. Nifedipine (e.g., Adalat) is the least appropriate choice for patients with diabetic nephropathy.
Topics: Albuminuria; Antihypertensive Agents; Calcium Channel Blockers; Diabetic Nephropathies; Humans; Nife | 1997 |
Effects of the antihypertensive drug nifedipine on albuminuria and renal histopathology in young spontaneously hypertensive rats with diabetes.
Topics: Albuminuria; Animals; Antihypertensive Agents; Creatinine; Diabetes Mellitus, Experimental; Diabetic | 1999 |
A case of nephrotic syndrome and renal dysfunction in a pregnant woman with diabetes mellitus.
Topics: Adult; Basement Membrane; Biopsy; Calcium Channel Blockers; Capillaries; Diabetic Nephropathies; End | 1992 |
Hypoglycemia associated with the administration of angiotensin-converting enzyme inhibitor in a diabetic hemodialysis patient.
Topics: Adult; Captopril; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Enalapril; Humans; Hypertension | 1991 |
The effect of antihypertensive treatment on kidney function in insulin-dependent (type I) diabetics with renal failure.
Topics: Acute Kidney Injury; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Mellitus, Type 1; | 1990 |